Mills GB - Search Results

1

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. Stemke-Hale K, et al. Among authors: mills gb. Cancer Res. 2008 Aug 1;68(15):6084-91. doi: 10.1158/0008-5472.CAN-07-6854. Cancer Res. 2008. PMID: 18676830 Free PMC article.

2

Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.

Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, Ullrich A, Sela M, Yarden Y. Bacus SS, et al. Among authors: mills gb. Cancer Res. 1992 May 1;52(9):2580-9. Cancer Res. 1992. PMID: 1373672

3

MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.

Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA, et al. Teng DH, et al. Among authors: mills gb. Cancer Res. 1997 Dec 1;57(23):5221-5. Cancer Res. 1997. PMID: 9393738

4

Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.

Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC Jr. Xu FJ, et al. Among authors: mills gb. Clin Cancer Res. 1997 Sep;3(9):1629-34. Clin Cancer Res. 1997. PMID: 9815853

5

Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis.

Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Davies MA, et al. Among authors: mills gb. Cancer Res. 1998 Dec 1;58(23):5285-90. Cancer Res. 1998. PMID: 9850049

6

NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC Jr. Yu Y, et al. Among authors: mills gb. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9. doi: 10.1073/pnas.96.1.214. Proc Natl Acad Sci U S A. 1999. PMID: 9874798 Free PMC article.

7

PIK3CA is implicated as an oncogene in ovarian cancer.

Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. Shayesteh L, et al. Among authors: mills gb. Nat Genet. 1999 Jan;21(1):99-102. doi: 10.1038/5042. Nat Genet. 1999. PMID: 9916799

8

Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model.

Pusztai L, Siddik ZH, Mills GB, Bast RC Jr. Pusztai L, et al. Among authors: mills gb. Acta Oncol. 1998;37(7-8):629-40. doi: 10.1080/028418698429964. Acta Oncol. 1998. PMID: 10050979 Review.

9

The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.

Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC Jr. Xu F, et al. Among authors: mills gb. Clin Cancer Res. 1999 Nov;5(11):3653-60. Clin Cancer Res. 1999. PMID: 10589783

10

Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC Jr, Mills GB. Pustilnik TB, et al. Among authors: mills gb. Clin Cancer Res. 1999 Nov;5(11):3704-10. Clin Cancer Res. 1999. PMID: 10589790

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,143 results

Search Page

Filters